Gimple L W, Gertz S D, Haber H L, Ragosta M, Powers E R, Roberts W C, Sarembock I J
Division of Cardiology, University of Virginia Health Sciences Center, Charlottesville 22908.
Circulation. 1992 Nov;86(5):1536-46. doi: 10.1161/01.cir.86.5.1536.
Heparin is known to have antithrombotic, anticoagulant, and antiproliferative effects. We hypothesized that chronic subcutaneous and/or direct intramural administration of heparin would reduce restenosis and inhibit plaque growth after balloon angioplasty.
Focal atherosclerosis was induced bilaterally in the femoral arteries of 59 rabbits by air desiccation intimal injury and a 2% cholesterol diet. After angioplasty, the rabbits were assigned to one of four treatment groups. Control arteries (n = 21) received no additional heparin. A second group of 20 arteries was treated with a porous balloon that delivered heparin (1,500 units) directly into the arterial wall. A third group (n = 29) received subcutaneous heparin (350 units.kg-1.day-1) for 28 days, and a fourth group (n = 23) was treated with subcutaneous and intramural heparin. Quantitative angiography showed a modest reduction in restenosis (defined as the change in minimal luminal diameter from immediately after angioplasty to 28 days) with subcutaneous heparin compared with control arteries (0.32 +/- 0.18 versus 0.58 +/- 0.34 mm, p < 0.01); however, luminal diameter was not improved at 28 days compared with before angioplasty. Intramural delivery of heparin by the porous balloon catheter was confirmed by use of fluoresceinated heparin in one animal. Angiographic restenosis was not reduced in arteries treated with intramural heparin versus controls (0.61 +/- 0.54 versus 0.58 +/- 0.34 mm, p = NS). Blinded planimetric analysis of histological sections showed no differences in luminal cross-sectional area narrowing by atherosclerotic plaque, in plaque area, or in plaque/media ratio at 28 days among the four treatment groups.
Chronic subcutaneous heparin after balloon angioplasty results in a modest reduction in angiographic restenosis in this model; however, the absolute luminal diameter is not improved compared with before angioplasty, and plaque area and percent luminal narrowing by plaque were not different among the four treatment groups. Heparin can be delivered into an atherosclerotic plaque by a porous balloon, but this treatment does not reduce restenosis after angioplasty in this model.
肝素具有抗血栓形成、抗凝和抗增殖作用。我们推测,长期皮下和/或直接壁内给予肝素可减少球囊血管成形术后的再狭窄并抑制斑块生长。
通过空气干燥内膜损伤和2%胆固醇饮食在59只兔双侧股动脉诱导局灶性动脉粥样硬化。血管成形术后,将兔分为四个治疗组之一。对照动脉(n = 21)未接受额外的肝素。第二组20条动脉用可将肝素(1500单位)直接输送至动脉壁的多孔球囊进行治疗。第三组(n = 29)接受皮下肝素(350单位·kg-1·天-1)治疗28天,第四组(n = 23)接受皮下和壁内肝素治疗。定量血管造影显示,与对照动脉相比,皮下肝素治疗后再狭窄(定义为从血管成形术后即刻至28天最小管腔直径的变化)有适度降低(0.32±0.18对0.58±0.34 mm,p < 0.01);然而,与血管成形术前相比,28天时管腔直径未改善。在一只动物中使用荧光素标记的肝素证实了通过多孔球囊导管壁内输送肝素。与对照组相比,壁内肝素治疗的动脉造影再狭窄未降低(0.61±0.54对0.58±0.34 mm,p = 无显著性差异)。对组织学切片进行的盲法平面测量分析显示,四个治疗组在28天时动脉粥样硬化斑块导致的管腔横截面积狭窄、斑块面积或斑块/中膜比值方面无差异。
在该模型中,球囊血管成形术后长期皮下给予肝素可使造影再狭窄适度降低;然而,与血管成形术前相比,绝对管腔直径未改善,且四个治疗组之间斑块面积和斑块导致的管腔狭窄百分比无差异。肝素可通过多孔球囊输送至动脉粥样硬化斑块,但在该模型中这种治疗不能减少血管成形术后的再狭窄。